D De Cock Selected Research

W 7 (W7)

1/2015

Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

D De Cock Research Topics

Disease

6	Rheumatoid Arthritis 11/2022 - 01/2014
1	Hypertension (High Blood Pressure) 10/2023
1	Infertility (Sterility) 10/2020
1	Rheumatic Diseases (Rheumatism) 01/2015
1	Joint Diseases (Joint Disease) 01/2015

Drug/Important Bio-Agent (IBA)

3	Antirheumatic Agents (DMARD)IBA 11/2022 - 01/2014
2	GlucocorticoidsIBA 01/2015 - 01/2014
1	oxidized low density lipoproteinIBA 10/2023
1	LDL CholesterolIBA 10/2023
1	Etanercept (Enbrel)FDA Link 11/2022
1	Hormones (Hormone)IBA 10/2020
1	W 7 (W7)IBA 01/2015
1	Methotrexate (Mexate)FDA LinkGeneric 01/2015
1	Prednisone (Sone)FDA LinkGeneric 01/2015
1	C-Reactive ProteinIBA 01/2015
1	Leflunomide (Arava)FDA LinkGeneric 01/2015
1	ametantrone (HAQ)IBA 01/2015
1	SteroidsIBA 01/2014

Therapy/Procedure

2	Therapeutics 01/2015 - 01/2014
1	Secondary Prevention 10/2023
1	Drug Therapy (Chemotherapy) 10/2020
1	Remission Induction 01/2015
1	Treatment Delay 01/2014